Renal cell carcinoma (RCC) is one of the most aggressive urologic cancers, however, the mechanism on supporting RCC carcinogenesis is still not clear. By using gene expression profile analysis and functional clustering, PDZ domain-containing 1 (PDZK1) was revealed to be downregulated in human clear cell renal cell carcinoma (ccRCC) samples, which was also verified in several independent public ccRCC data sets. Using PDZK1 overexpression and knockdown models in ccRCC cell lines, we demonstrated that PDZK1 inhibited cell proliferation, cell cycle G1/S phase transition, cell migration and invasion, indicating a tumor-suppressor role in the development and progression of ccRCC. Our study further demonstrated that PDZK1 inhibited cell proliferation and migration of ccRCC via targeting SHP-1. PDZK1 was further identified to suppress cell proliferation by blocking SHP-1 phosphorylation at Tyr536 via inhibition of the association between SHP-1 and PLCβ3, and then retarding Akt phosphorylation and promoting STAT5 phosphorylation in ccRCC cells. Moreover, the inhibitive effects of PDZK1 on SHP-1 phosphorylation and the tumor growth were verified in vivo by xenograft tumor studies. Accordingly, PDZK1 expression was negatively correlated with SHP-1 activation and phosphorylation, advanced pathologic stage, tumor weight and size, and prognosis of ccRCC patients. These findings have provided first lines of evidences that PDZK1 expression is negatively correlated with SHP-1 activation and poor clinical outcomes in ccRCC. PDZK1 was identified as a novel tumor suppressor in ccRCC by negating SHP-1 activity.
INTRODUCTION
Renal cell carcinoma (RCC) is an aggressive urologic cancer type. Its incidence increases annually~2%.
1 Clear cell renal cell carcinoma (ccRCC) accounts for 75% of all kidney tumors. 2 Chemotherapy and radiotherapy are less-effective treatments against ccRCC. Recent advances in molecular biology have revealed that angiogenesis and tumor cell proliferation have important roles for the development and progression of ccRCC. 3, 4 These findings provide a theoretical basis for ccRCC-targeted therapies and have greatly changed the therapeutic landscape in ccRCC.
It has been well known that inactivation of tumor-suppressor VHL (Von Hippel-Lindau) results in an accumulation of hypoxiainducible factor (HIF), which contributes to neoangiogenesis in 480% ccRCC. 5, 6 Thus, at present, most RCC-targeted drugs are mainly designed to inhibit angiogenic pathways, 7 but have only achieved a limited survival-time improvement. 8 Traditionally, the evaluation of the parameters of tumor cell proliferation including tumor size, mitotic index, proliferation cell nuclear antigen and Ki67 antigen have been suggested as having prognostic importance in RCC. 9 However, the molecular mechanisms on the deregulation of cell proliferation in RCC is still largely unknown. Uncovering these mechanisms may aid in the clarity of the pathogenesis of RCC and advancement of more effective therapy.
Recently, there has been an increasing interesting for the PDZ domain-containing proteins, which have essential roles in tumor growth, development and metastasis. 10 Studies have established that several PDZ proteins including TIP-1, DLG, Erbin and NHERF1 are involved in tumorigenesis such as colorectal and breast cancers. [11] [12] [13] [14] The NHERF family of PDZ proteins are commonly expressed in polarized epithelia. 15 Abnormal expression of NHERF1 has been found in several types of tumors, such as hepatocellular carcinoma, breast cancer and nerve schwannoma.
14 NHERF1 expression is also related to cancer invasion and metastasis. 16 Over 150 PDZ proteins have been found in the human proteome, and many of which are highly expressed in renal epithelial cells. 17 However, the roles of PDZ proteins in renal cancer carcinogenesis and progression are largely unknown.
In this study, differential gene expression analysis using the available mRNA expression profile of ccRCC from GEO data set combined with GO analysis was used for the screening of target PDZ proteins associated with cell proliferation. Among 2267 downregulated genes, PDZK1, a member of PDZ proteins, is downregulated and associated with cell proliferation in ccRCC. Loss of PDZK1 is demonstrated to be correlated with advanced clinical stage and adverse prognosis in ccRCC. PDZK1 retarded cell growth and promoted cell cycle arrest of ccRCC cells in vivo and in vitro by blocking SHP-1 phosphorylation through suppression of SHP-1 binding to PLCβ3. These data support a novel tumor-suppressor role of PDZK1 and provide a new insight into the development and progression of ccRCC.
RESULTS

Low expression of PDZK1 predicts poor survival in ccRCC
To identify aberrantly expressed genes associated with ccRCC carcinogenesis and progression, the mRNA expression profile obtained from GSE53757 (http://www.ncbi.nlm.nih.gov/geo/) with 72 paired ccRCC and adjacent non-tumor renal tissues were analyzed. Totally, 2267 genes were significantly downregulated in ccRCC tissues by GEO2R analysis. DAVID (Database for Annotation, Visualization and Integrated Discovery, developed by NIAID/NIH) was then used to investigate gene ontology (GO) term enrichment. GO analysis revealed that 40 genes, related to the biological process of 'cell proliferation', and 10 genes associated with the molecular function of 'PDZ domain binding', were downregulated in ccRCC tissues. Only TGFBR3 and PDZK1 genes were associated to both 'cell proliferation' and 'PDZ domain binding' (P o 0.001; Supplementary Figure S1 ). TGFBR3 has been involved in ccRCC carcinogenesis. 18 However, the role and relevance of PDZK1 in ccRCC are still largely unknown, so we focused on exploring physiological and pathological significance of PDZK1 in this study.
To verify these findings, the expression of PDZK1 mRNA in ccRCC and their adjacent tissues were analyzed either with GEO ccRCC data set or TCGA's RNA-seq data of ccRCC patients; all the results showed that PDZK1 mRNA expression level was obviously downregulated in ccRCC tissues as compared with adjacent nontumor renal tissues (Figures 1a and b) . Further analysis of PDZK1 mRNA levels from five independent published studies in ONCOMINE database entirely confirmed our results that PDZK1 mRNA expression was significantly lower in ccRCC tissues than that in normal renal tissues (Figure 1c) . Moreover, analysis of PDZK1 protein expression in tissue microarray of 90 ccRCC specimens also confirmed that PDZK1 expression was reduced in ccRCC tissues at protein level (Figures 1d and e) .
To explore the clinical relevance of PDZK1 in ccRCC, the correlation between PDZK1 expression levels and tumor stages was evaluated. The results showed that PDZK1 was negatively correlated with the tumor stage either at protein (Figures 1f, Po 0.05) or mRNA (Figures 1g, P o 0.01) levels, also tumor weight and volume ( Supplementary Figures S2a and b) . In addition, we found that PDZK1 was negatively correlated with the T stage, which reflected the tumor size, either at protein (Supplementary Figure S2c , P o 0.05) or mRNA (Supplementary Figure S2d , Po 0.05) levels. All these data indicate that loss of PDZK1 expression is associated with advanced tumor stage and tumor growth. Also we found that lower PDZK1 expression correlated with poor clinical outcome of ccRCC patients.
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PDZK1 inhibits cell proliferation, migration and invasion of ccRCC cells Tumor cell proliferation is a major representative indicator of malignant phenotypes. PDZK1 was related to cell proliferation by GO analysis using the DAVID online analysis tool, so the effects of PDZK1 expression on ccRCC cell proliferation were investigated.
The 769-P and 786-O ccRCC cells were stably transfected with PDZK1 expression constructs, and the overexpression of PDZK1 was confirmed by western blotting (Figure 2a ). Then cell viability and colony formation were measured. The results showed that PDZK1 overexpression in 769-P and 786-O cells led to reduced cell proliferation ( Figure 2b ) and decreased colonogenicity (Figure 2c ). To further confirm the results, PDZK1 was knocked down in 769-P and 786-O cells, by stable transfection with small hairpin RNAs, shPDZK1#1 and shPDZK1#2, respectively. Significantly decreased PDZK1 expression was verificated by western blotting (Figure 2d ), and the cell proliferation increased robustly in PDZK1 knockdown cell lines (Figure 2e ). These data confirmed that PDZK1 expression inhibited ccRCC cell proliferation. To explore the possible mechanism of cell proliferation inhibition by PDZK1, we further investigated the effects of PDZK1 on cell cycle progression using flow cytometry. As shown in Figure 2f , after depletion of PDZK1, the percentage of 769-P cells in G0/G1 phase obviously decreased from 66.5 to 48.1%, whereas the distribution of cells in S phase increased from 20.7 to 37.2%. The data demonstrated that PDZK1 induced cell cycle arrest at G1/S checkpoint in ccRCC cells. Taken together, PDZK1 expression inhibited cell growth and promoted cell cycle arrest of ccRCC cells.
The effects of PDZK1 expression on the migration or invasion ability of ccRCC cells were also evaluated by scratch or transwell assays. The results showed that overexpression of PDZK1 in 769-P and 786-O cells inhibited tumor cell migration (Figure 3a ) and invasion ( Figure 3b ) as compared with control cells.
To further verify the pathways associated with the pathogenesis of ccRCC, the patients were stratified by the median levels of PDZK1 and gene set enrichment analysis (GSEA) was performed with TCGA ccRCC data sets; data showed that the gene signatures of cell proliferation, cell cycle and migration were enriched in patients with low PDZK1 expression, suggesting that PDZK1 repressed cell proliferation and migration abilities in ccRCC tissues (Supplementary Figure S3) . Taken together, our results indicate that PDZK1 elicits a tumor-suppressive role via regulation of cell proliferation and migration in ccRCC.
PDZK1 inhibits cell proliferation and migration of ccRCC via targeting SHP-1 The PTPase (phosphatase) activity of SHP-1 has an important role in cell proliferation and migration, 20 so the roles of SHP-1 in PDZK1-mediated proliferation and migration were studied in ccRCC cells. NSC-87877, a potent inhibitor of SHP-1 phosphatase, was used to inhibit the SHP-1 activity in 769-P cell. As shown in Figure 4 , the proliferation of 769-P cells was dose-and timedependently inhibited by NSC-87877, suggesting that SHP-1 activity is essential for ccRCC cell proliferation (Figures 4a and b) . To illuminate whether PDZK1 suppresses ccRCC cell proliferation and migration by targeting SHP-1, cell proliferation and migration assays were performed by treating the 769-P cells with NSC-87877 in the presence or absence of PDZK1. PDZK1 showed no effects on the proliferation and migration of 769-P cells when SHP-1 activity was inhibited by NSC-87877 (Figures 4c and d) . To confirm these results, cell proliferation in 769-P cells was detected after combined knockdown of PDZK1 and SHP-1. The results showed that silencing PDZK1 expression significantly promoted cell proliferation in 769-P cells when SHP-1 existed. However, PDZK1 had no effects on cell proliferation when SHP-1 was knocked down (Figure 4e ). Taken together, these data indicated that PDZK1 inhibits cell proliferation and migration of ccRCC by targeting SHP-1.
PDZK1 inhibits SHP-1 phosphorylation at Tyr536 via suppression of SHP-1/PLCβ3 binding, leading to reduction of Akt phosphorylation and promotion of STAT5 phosphorylation in ccRCC cells Lines of evidences showed that phosphatase activity of SHP-1 was regulated by SHP-1 phosphorylation. 21 To explore the regulatory mechanism of PDZK1 on SHP-1 activity, PDZK1 expression was changed by overexpression or knockdown in 786-O cells and SHP-1 phosphorylation was detected. As shown in Figures 5a and b, PDZK1 overexpression suppressed Tyr536 phosphorylation of SHP-1 in a dose-dependent manner. Conversely, PDZK1 knockdown increased the SHP-1 phosphorylation in 786-O cells ( Figure 5c ). Consistently, the inhibitive effects of PDZK1 on SHP-1 phosphorylation were verified in 769-P cells (Supplementary Figure S4) . (f) PDZK1 knockdown led to S phase accumulation in 769-P cells. Cell transfected with mixed two PDZK1 siRNAs and cell cycle analysis was performed using propidium iodide DNA staining and flow cytometry (t-test, Po 0.01). All data were representatives of at least three independent experiments.
The previous report showed that SHP-1 phosphorylation was regulated by PLCβ3. 22 Therefore, we further explored the potential roles of PLCβ3 in PDZK1-mediated suppression on SHP-1 phosphorylation. As the results shown in Figure 5d , knockdown of PLCβ3 robustly abolished SHP-1 phosphorylation at Tyr536 in 786-O cells, and PDZK1 knockdown significantly increased SHP-1 phosphorylation only when PLCβ3 existed. These results suggested that PDZK1 inhibition of SHP-1 phosphorylation at Tyr536 required PLCβ3.
SHP-1 phosphatase activity was generally assessed by the impact on phosphorylation of its target molecules such as STAT3, STAT5 and Akt. 20, 22, 23 To identify the cellular targets of SHP-1 in renal cancer cells, the phosphorylation of STAT3，STAT5 and Akt were explored in 769-P cells, in which PDZK1 was overexpressed and knocked down, respectively. The results showed that PDZK1 significantly promoted STAT5 phosphorylation, and robustly inhibited Akt phosphorylation, with no detectable impact on STAT3 phosphorylation (Figures 6a and b) . To further confirm our initial findings, the correlation between PDZK1 mRNA levels and activation of Akt or STAT3 signaling in ccRCC specimens was investigated by GSEA. The results demonstrated a negative correlation between PDZK1 level and the activation of Akt signaling (Figure 6c ), but no correlation between PDZK1 and STAT3 activation was found in ccRCC samples (Figure 6d ). The data are in line with the results of our in vitro study. Unfortunately, a gene set of STAT5 signaling activation was currently not available yet, we were therefore unable to detect the correlation of PDZK1 with STAT5 signaling activation in ccRCC specimens. Taken together, our results indicate that PDZK1/SHP-1 inhibits ccRCC development and progression by regulation of Akt signaling, including possibly STAT5 signaling. These need to be validated with further studies. Studies have shown that PLCβ3 bond SHP-1 via C-terminal of PLCβ3 to facilitate the SHP-1 phosphorylation at Tyr536. 22 Meanwhile, PLCβ3 can also interact with PDZK1 via its PDZbinding motif at the C-terminus. 24 Our results also verified these interactions endogenously in 786-O cell (Figures 7a and b) , and deletion of the PDZ-binding motif in C-terminus of PLCβ3 (PLCβ3-△NTQL) completely abolished its interaction with PDZK1 ( Figure 7c) . Interestingly, the mutation of PLCβ3-ΔNTQL inhibited 769-P cell migration through suppressing SHP-1 activation. 769-P cells transfected with siRNA control or two mixed PDZK1 siRNAs were cultured, respectively, and treated in the presence or absence of SHP-1 PTPase inhibitor NSC-87877 (100 μM) for 24 h. The migration of wound-healing assay was subsequently calculated (t-test, Po 0.05). (e) PDZK1 inhibited 769-P cell growth dependent on SHP-1 expression. 769-P and 769-P-shPDZK1 cells were transfected with either SHP-1 siRNA#1, siRNA#2 or scramble control, respectively, and cell proliferation was determined as described in Figure 2b . All data were representatives of three independent experiments and data are shown as mean ± s.d. *Po 0.05, **Po 0.01.
PDZK1 a novel tumor suppressor in ccRCC T Tao et al significantly enhanced the association of PLCβ3 and SHP-1 ( Figure 7d) ; reminding that interaction between PDZK1 and PLCβ3 retarded the association of SHP-1 and PLCβ3. To verify this result, GST-PLCβ3-CT was used to pull down endogenous SHP-1 in the absence or presence of different doses of His-PDZK1-PDZ1. As shown in Figure 7e , the PDZ1 domain of PDZK1 exhibited a dosedependent inhibition of the association between PLCβ3 and SHP-1. This result was further confirmed in HEK293T cells by cotransfection of Flag-PLCβ3 with different amounts of Myc-PDZK1 constructs. Immunoprecipitation of Flag-PLCβ3 followed by western blotting analysis of SHP-1 revealed that SHP-1 coimmunoprecipitation with PLCβ3 was concordantly reduced with a gradual increase of PDZK1 protein level (Figure 7f ). Taken together, these results indicate that PDZK1 retards SHP-1 phosphorylation via inhibiting the association between SHP-1 and PLCβ3.
PDZK1 inhibits the ccRCC cell proliferation in vivo by blocking SHP-1 phosphorylation To examine the roles of PDZK1 in vivo, a model of xenograft tumor was generated through subcutaneously injecting PDZK1 overexpressed or control ccRCC cells into nude mice. Overexpression of PDZK1 suppressed the growth of ccRCC xenografts within 16 days (Figure 8a) . Accordingly, the weight and volume of tumors were significantly decreased in PDZK1 overexpressed group as compared with the control (Figures 8b-d) . Immunohistochemical staining analysis showed that PDZK1 overexpression decreased the Tyr536 phosphorylation of SHP-1, and reduced the expression of Ki67, the cell proliferation marker (Figure 8e ). These results suggest that PDZK1 suppresses tumor cell proliferation by inhibiting the phosphorylation of SHP-1 in xenograft tumor of ccRCC cells. To further explore the correlation of PDZK1 and SHP-1 phosphorylation in ccRCC tissues, the expression levels of PDZK1 and phosphorylated SHP-1 were examined with western blotting. As compared with the paracancerous tissues, PDZK1 protein level was markedly decreased in ccRCC tissues. Accordingly, SHP-1 phosphorylation levels were significantly increased in ccRCC tissues (Figure 9a) .
To delineate relevance of SHP-1 activation in ccRCC development and progression, gene signatures in response to SHP-1 activation were analyzed in TCGA database of ccRCC patients. Data showed that the gene signatures specific to SHP-1 activation were enriched in ccRCC patients with cancer or poor prognosis (Figure 9b and c) , suggesting that SHP-1 activation was positively associated with ccRCC development and progression. To further verify whether loss of PDZK1 expression is associated with SHP-1 activation, GSEA was also used to test the enrichment value of SHP-1 activation related with PDZK1 mRNA levels. Results showed that gene signatures of SHP-1 activation were positively enriched in PDZK1 low expression group (false discovery rate = 0.001) (Figure 9d ). These findings provide first lines of evidences that PDZK1 levels are negatively correlated with SHP-1 activation, suggesting that loss of PDZK1 in ccRCC patients may contribute to the tumorigenesis and progression of ccRCC via activation of SHP-1 (Figure 9e ). PDZK1 a novel tumor suppressor in ccRCC T Tao et al DISCUSSION Aberrant PDZK1 expression has been observed in several kinds of cancers, and it is involved in tumor cell signaling via its PDZ domain mediated protein-protein interaction. 25, 26 However, the role and relevance of PDZK1 in renal cancer are largely unknown. Here, we identified PDZK1 as a downregulated gene in ccRCC through the analysis of mRNA expression profile obtained from the GEO series GSE53757, and revealed PDZK1 as a cell proliferation-related PDZ protein by functional clustering analysis. We provided the evidences that PDZK1 has tumor-suppressive roles in ccRCC. PDZK1 was significantly decreased in ccRCC at mRNA and protein levels. Loss of PDZK1 was in positive correlation with advanced tumor stage and larger tumor size of ccRCC (Figure 1 and Supplementary Figure S2) . Studies in ccRCC cells revealed that PDZK1 overexpression inhibited cell proliferation, migration and invasion (Figure 2 and Figure 3) , whereas PDZK1 knockdown enhanced cell proliferation (Figures 2d and e) . Furthermore, PDZK1 overexpression inhibited tumor growth of xenografts derived from ccRCC cells in nude mice (Figure 8 ). These findings support that PDZK1 plays a crucial role in renal carcinogenesis and progression.
It is well known that PDZK1 can interact with multiple proteins and regulate downstream cell signaling. 24, 27 Here we showed that PDZK1 interacts with PLCβ3 and affects SHP-1 activation. SHP-1, a member of protein tyrosine phosphatases (PTPs), is previously reported to be largely expressed in the hematopoietic cells and has a role as a tumor suppressor. 28 In solid tumors, SHP-1 is also broadly expressed, however, its expression has been found to correlate with worse survival of breast cancer, glioma and prostate cancer. 20, 29, 30 It indicates that SHP-1 had tumor-promoting activity in solid tumors. In this study, we found that suppression of SHP-1 activation or expression by its selective inhibitor NSC-87877 or siRNA retarded ccRCC cell proliferation and migration. Also we showed that PDZK1 suppressed cell proliferation, migration of ccRCC cells by targeting SHP-1 (Figure 4) . To explore the molecular mechanism by which SHP-1 regulates the renal cancer cells, the activation or phosphorylation of potential target proteins of SHP-1, such as Akt, STAT3 and STAT5, and the levels of total tyrosine phosphorylation were detected. Our results showed that no significant change was found in either levels of total tyrosine phosphorylation or STAT3 phosphorylation in ccRCC cells with SHP-1 or PDZK1 knockdown, as well as in the cell pretreated with NSC-87877 (Supplementary Figure S5) . However, with either overexpression or knockdown in 769-P cells, PDZK1 was demonstrated to inhibit Akt phosphorylation, and promote STAT5 phosphorylation. Rodríguez-Ubreva FJ et al. 20 previously reported that SHP-1 promoted Akt Ser473 phosphorylation via inhibiting Tyr phosphorylation of p110 catalytic subunit of PI3K, our results suggested that PDZK1 retarded Akt phosphorylation possibly via regulating SHP-1-PI3K-Akt pathway. This negative correlation between PDZK1 and Akt activation was also confirmed in the result analyzed with clinical ccRCC specimens using GSEA method (Figure 6c ).Take together, these data indicate that PDZK1 or SHP-1 is unable to alter general tyrosine phosphorylation; however, SHP-1 could selectively dephosphorylate some specific target proteins as Akt or STAT5, and then inhibit ccRCC development and progression. These results need to be validated with further studies.
SHP-1 is composed of two tandem domains of N-SH2 and C-SH2, followed by the catalytic domain of PTP and C-terminal tail, which contains key tyrosine phosphorylation sites in the regulation of SHP-1 activity.
21 N-SH2 is located closely to the PTP catalytic domain of SHP-1, which restricts accession of PTP catalytic domain and substrate of phosphatase. When SHP-1 Tyr536 phosphorylated, the PTP catalytic domain was separated from N-SH2 to become accessible for its substrates (Figure 9e ). This is confirmed by that reduced SHP-1 phosphorylation at Tyr536 results in a drastic reduction of SHP-1 phosphatase activity. 22 Recent reports reveal that PLCβ3 acts as a scaffold to associate with SHP-1 and recruits tyrosine kinase to phosphorylate SHP-1 by forming a macromolecular complex. 22 In the current study, we showed that PLCβ3 knockdown inhibited SHP-1 phosphorylation in ccRCC cells (Figure 5d ), indicating that PLCβ3 is required for the SHP-1 phosphorylation at Tyr536. Our study also showed that PDZK1 dose-dependently inhibited SHP-1 phosphorylation through blocking the association between SHP-1 and PLCβ3 (Figures 5a and b, Figures 7e and f) . Taken together, our data suggest that PDZK1 inhibits SHP-1 phosphorylation by suppression of the association between SHP-1 and PLCβ3.
As a member of PLCβ family, PLCβ3 generally has its function via the phospholipase activity-dependent pathway. 31 Recently, studies have shown that PLCβ3 can also act as a scaffold to recruit some tyrosine kinases via its non-catalytic C-terminal domain to facilitate SHP-1 phosphorylation. 22 In this study, we found that PDZK1 retarded SHP-1 phosphorylation via the inhibition of the association between SHP-1 and PLCβ3. Interestingly, PLCβ3 is found to be upregulated and correlated with poor prognosis in renal cancer patients (data not shown). These results are consistent with the finding that upregulated PLCβ3 increased the phosphorylation of SHP-1 in ccRCC cells, indicating that PLCβ3 may have a tumor-promoting role in Figure 9 . SHP-1 PTPase activity is upregulated in ccRCC, positively correlated with poor prognosis and negatively correlated with PDZK1 expression levels in ccRCC patients. (a) Negative correlation between expression levels of PDZK1 and SHP-1 phosphorylation. The expression levels of PDZK1 and phosphorylated SHP-1 of ccRCC specimens and their adjacent tissues were analyzed by western blotting, and total expression levels of SHP-1 and GAPDH were shown as loading controls. (b-d) SHP-1 is activated in ccRCC, and its activity is positively correlated with poor prognosis and low PDZK1 expression of ccRCC. The gene signatures of SHP-1 activation was significantly enriched in ccRCC, poor prognosis and low PDZK1 expression groups as compared with normal, good prognosis and high PDZK1 expression groups, respectively. (e) Schematic illustration of the mechanism of the enhancement of SHP-1 phosphorylation owing to loss of PDZK1 and its association with PLCβ3 in ccRCC.
PDZK1 a novel tumor suppressor in ccRCC T Tao et al renal cancer. However, this hypothesis need to be further explored.
In this study, we found that PDZK1 was significantly downregulated in ccRCC, and loss of PDZK1 was correlated with higher TNM staging in TCGA database. Similar results were obtained by a tissue microarray study of ccRCC patient specimens. Importantly, loss of PDZK1 was remarkably correlated with poor prognosis of ccRCC patients.
As we know, VHL-HIF-1α pathway has a critical role in ccRCC. To investigate whether VHL-HIF-1α pathway is involved in PDZK1-mediated inhibition on the development and progression of ccRCC, cell lysates of 769-P and 786-O were immunoblotted, respectively, to detect HIF-1α expression, and no detectable expression of HIF-1α was observed in either 769-P and 786-O cells (Supplementary Figure S6a) . GSEA results show that PDZK1 expression has no correlation with gene signatures of HIF-1/2α signaling activation in clinical ccRCC specimens (Supplementary Figure S6b and c) , indicating that PDZK1 inhibits the development and progression of ccRCC probably independent of VHL-HIF pathway.
In conclusion, PDZK1 is identified as a novel tumor suppressor in ccRCC and has been demonstrated its inhibition on proliferation, migration and invasion by targeting SHP-1. Loss of PDZK1 expression is correlated with SHP-1 activation and poor clinical outcomes in ccRCC. Taken together, our findings provide novel clues for understanding of ccRCC carcinogenesis.
MATERIALS AND METHODS
Reagents and antibodies
NSC-87877 (565851), a SHP-1 selective inhibitor, was purchased from Calbiochem (Millipore, Billerica, MA, USA). The following antibodies were purchased: anti-His antibody from MBL (Nagoya, Japan), anti-Myc antibody from Applygen (Beijing, China), anti-PDZK1 antibody and anti-phosphor-SHP-1 (Tyr536) antibody from Abcam (Cambridge, UK), anti-PLCβ3 and anti-SHP-1 from Santa Cruz (Dallas, TX, USA), anti-FLAG M2 antibody and FLAG M2-agarose from Sigma (St Louis, MO, USA), anti-STAT5, anti-phosphor-STAT5 (Tyr694), anti-STAT3, anti-phosphor-STAT3 (Tyr705), anti-phosphorAkt (Ser473) and anti-Akt from CST (Danvers, MA, USA), HRP-conjugated secondary antibodies and anti-GAPDH from ZSGB-BIO (Beijing, China).
Data sets collection and ccRCC patient samples
Totally six ccRCC tissues and matched adjacent renal tissues were collected from the First Hospital of Shanxi Medical University of Taiyuan during 2010. Patients who signed the informed consents were included. This study has been approved by Ethics Committee of Shanxi Medical University. The tissue microarrays of ccRCC, containing biopsies from 90 ccRCC and its adjacent renal tissues, were purchased from Shanghai Outdo Biotech (Shanghai, China).
The GEO data set GSE53757, which consisted of 72 paired renal cancer and adjacent renal tissues, was used for the differential expression genes screening and GO analyses. TCGA ccRCC RNA-Seq and matching clinical data were collected from Synapse website (http://synapse.org; syn1461159). RNA-Seq analysis was performed with the TCGA data of 531 ccRCC and 72 adjacent renal tissues.
GEO2R and GO analyses GEO2R analyzer, a software tool for analyzing the data in GEO database, was used to analyze the public available GSE53757 data. 32 A total of 144 samples were divided into two groups: 72 ccRCC tissues and 72 matched adjacent renal tissues. The cutoff criteria for screening differentially-expressed mRNAs was: Po0.05 and the fold change of expression levels42.0. To explore the functional annotation enrichment of genes, the GO analyses were performed with DAVID tools (http://david.abcc.ncifcrf.gov/).
Gene set enrichment analysis GSEA was carried out as previously 33 to assess user-defined gene sets described as follows: SHP-1 activation gene set was defined as genes upregulated at least 1.5-fold changes associated with stimulation of SHP-1 PTPase activities (GSE42922). Akt signaling gene set (HALLMARK_PI3-K_Akt_SIGNALING) and STAT3 signaling gene set (AZARE_STAT3_TARGETS) were obtained from Molecular Signatures Database from the Broad Institute (http://software.broadinstitute.org/gsea/msigdb). Tests were performed by using the default settings, and permutations number was set at 1000. False discovery rate o 0.25 was considered statistically significant.
Immunohistochemistry
The samples used for immunohistochemistry analysis include tissue microarray of human tissues, and mice tumor xenograft. Immunohistochemistry was performed as described previously. 34 Primary antibodies were incubated at the optimal conditions (PDZK1, 1:100, Abcam; pSHP-1, 1:100, Abcam; Ki67, 1:100, Santa Cruz). Omitting primary antibodies were used as negative control. IPP software was used to analyze optical densitometry.
Cell culture and transfection
